ACUTAAS vs NEPHROPLUS: Stock Comparison
Acutaas Chemicals Limited is the larger company by market capitalisation. Acutaas Chemicals Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ACUTAAS leads 12; NEPHROPLUS leads 1 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ACUTAAS | NEPHROPLUS |
|---|---|---|
| Sector | Healthcare | — |
| Industry | Pharmaceuticals | — |
Price
| Metric | ACUTAAS | NEPHROPLUS |
|---|---|---|
| Live Price | ₹3,313.4 | ₹697.35 |
| Day Change | 4.42% | 1.47% |
| Volume | 4.1 L | 1.46 L |
| 52-Week High | ₹3,740 | ₹769.75 |
| 52-Week Low | ₹1,302 | ₹446 |
| Distance from 52W High | -11.41% | -9.41% |
Valuation
| Metric | ACUTAAS | NEPHROPLUS |
|---|---|---|
| Market Cap | ₹27,017 Cr | ₹6,991 Cr |
| P/E Ratio | 67.17x | 89.97x |
| P/B Ratio | 15.69x | 6.19x |
| EPS | ₹34.9 | ₹7.66 |
| Book Value | ₹201.93 | ₹111 |
| Dividend Yield | 0.05% | 0% |
Growth
| Metric | ACUTAAS | NEPHROPLUS |
|---|---|---|
| Revenue Growth (TTM YoY) | 40.3% | 0% |
| EPS Growth (TTM YoY) | 105.6% | 0% |
| Qtr Sales Growth | 40.3% | 21.2% |
| Qtr Profit Growth | 111% | 22.1% |
Profitability & Leverage
| Metric | ACUTAAS | NEPHROPLUS |
|---|---|---|
| ROE | 24% | 9.06% |
| ROCE | 31.6% | 15.5% |
| Net Margin | 26.6% | 7.69% |
| Operating Margin | 35.9% | 22.4% |
| Debt to Equity | 0.02x | 0.07x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ACUTAAS | NEPHROPLUS |
|---|---|---|
| Promoter Holding | 32.66% | 21.07% |
| FII Holding | 21.61%▲ 2.13 pp | 8.78%▼ 1.16 pp |
| DII Holding | 19.56%▼ 0.04 pp | 9.05%▲ 0.4 pp |
| Public Holding | 26.16%▼ 2.08 pp | 18.32%▲ 0.76 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Acutaas Chemicals Limited and Nephrocare Health Services Ltd.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.